LeonaBio, Inc. (LONA)
NASDAQ: LONA · Real-Time Price · USD
6.06
+0.75 (14.25%)
At close: Mar 9, 2026, 4:00 PM EDT
6.17
+0.12 (1.90%)
After-hours: Mar 9, 2026, 4:10 PM EDT
LeonaBio Employees
LeonaBio had 26 employees as of December 31, 2024. The number of employees decreased by 41 or -61.19% compared to the previous year.
Employees
26
Change (1Y)
-41
Growth (1Y)
-61.19%
Revenue / Employee
n/a
Profits / Employee
-$1,450,885
Market Cap
56.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | -41 | -61.19% |
| Dec 31, 2023 | 67 | 3 | 4.69% |
| Dec 31, 2022 | 64 | 29 | 82.86% |
| Dec 31, 2021 | 35 | 13 | 59.09% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Acrivon Therapeutics | 78 |
| Kezar Life Sciences | 55 |
| MiNK Therapeutics | 23 |
| Plus Therapeutics | 21 |
| Lipocine | 16 |
| Nutriband | 13 |
| Alterity Therapeutics | 9 |
LONA News
- 4 weeks ago - LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - GlobeNewsWire
- 2 months ago - Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition? - Benzinga
- 2 months ago - Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript - Seeking Alpha
- 2 months ago - Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment - GeekWire
- 2 months ago - Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewsWire
- 6 months ago - Athira Pharma Announces Reverse Stock Split - GlobeNewsWire
- 10 months ago - Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit - GlobeNewsWire
- 10 months ago - Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - GlobeNewsWire